References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2013-2374

mrj-472

Research Article

Статьи

Articles

Комбинация напроксена и эзомепразола: обезболивающая терапия при соблюдении баланса кардиоваскулярного и желудочно-кишечного риска

A combination of naproxen and esomeprazole: Analgesic therapy on balancing cardiovascular and gastrointestinal risks

Каратеев

Андрей Евгеньевич

Karateev

Andrei Evgenyevich

aekarat@yandex.ru

Алексеева

Людмила Ивановна

Alekseeva

L I

Аникин

С. Г.

Anikin

S G

2013

15032013

№1 (2013)

8293

2013

Каратеев А.Е., Алексеева Л.И., Аникин С.Г.

Karateev A.E., Alekseeva L.I., Anikin S.G.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/472

Нестероидные противовоспалительные препараты (НПВП) — важнейший инструмент контроля боли при ревматических заболеваниях, однако их использование ограничивается опасностью развития серьезных осложнений со стороны сердечно-сосудистой системы и желудочно-кишечного тракта (ЖКТ). Появление в России нового препарата, представляющего собой фиксированную комбинацию напроксена и эзомепразола (Вимово™), расширяет возможности применения НПВП. В обзоре рассмотрены преимущества обоих компонентов этого препарата. Первый из них — напроксен, «традиционный» НПВП, широко используется во всем мире в качестве эффективного анальгетика. Его главным достоинством является наиболее низкий среди всех НПВП (кроме аспирина) риск развития осложнений со стороны сердечно-сосудистой системы. Эзомепразол — представитель группы ингибиторов протонной помпы, мощный антисекреторный препарат, прошедший серьезную проверку в качестве средства для профилактики осложнений со стороны ЖКТ, возникающих на фоне приема НПВП. Комбинация препаратов позволяет решить проблему недостаточной приверженности больных гастропротективной терапии. Масштабные клинические испытания подтвердили существенное снижение частоты ЖКТ-осложнений при использовании Вимово™ по сравнению с обычным кишечнорастворимым напроксеном, в том числе у лиц, получавших низкие дозы аспирина. Сравнение фиксированной комбинации напроксена и эзомепразола с целекоксибом показало, что новый препарат не уступает селективному ЦОГ2-ингибитору ни по эффективности, ни по ЖКТ-безопасности.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most important tool to control pain in rheumatic diseases; however, their application is limited by the risk of serious complications in the cardiovascular system and gastrointestinal tract (GIT). The advent of a Russian new drug that is a naproxen and esomeprazole combination (Vimovo™) extends the possibilities of NSAIDS use. This review considers the benefits of both NEC components. The former is naproxen, a traditional NSAIDS that is in common use as an effective analgesic worldwide. Its chief merit is the least cardiovascular risk among all NSAIDs (aside from aspirin). Esomeprazole is a representative of the group of proton pump inhibitors, a potent antisecretory drug that has passed major tests as an agent for the prevention of NSAID-related GIT complications. This drug combination allows patient incompliance to gastroprotective therapy to be eliminated. Large-scale clinical trials have confirmed a considerable reduction in the frequency of GIT complications with NSAIDS use as compared to the standard enteric-coated naproxen, including in patients receiving low-dose aspirin. Comparison of NEC with celecoxib has indicated that the new medication is as effective as a selective COX-2 inhibitor in both efficacy and GIT safety.

ревматические заболеваниянестероидные противовоспалительные препаратыгастропротективная терапияфиксированная комбинация напроксена и эзомепразола

diseasesnonsteroidal anti-inflammatory drugsgastroprotective therapya combination of naproxen and esomeprazole

References1

<div>Насонов Е.Л. Анальгетическая терапия в ревматологии: путешествие между Сциллой и Харибдой. Клин фармакол тер 2003;12(1):64-9.Lee Y. Effect and treatment of chronic pain in inflammatory arthritis. Curr Rheum Rep 2013;15(1):300.Van der Laar M., Pergolizzi J., Mellinghoff H. et al. Pain Treatment in Arthritis-Related Pain: Beyond NSAIDs. Open Rheum J 2012;6:320-30.Насонов Е.Л. Нестероидные противовоспалительные препараты (Перспективы применения в медицине). М.: Анко, 2000;142 с.Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009;167 с.Lain L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs -nice or necessary? Rew Gastroenterol Dis 2004;4:33-41.Fries J., Kristen N., Bennet M. et al. The rise and decline of nonsteroidal anti-inflammatory drag-associated gastropathy in rheumatoid arthritis. Arthr Rheum 2004;50:2433-40.Сороцкая В.Н., Каратеев А.Е. Желудоч но-кишечные осложнения как одна из причин смерти больных с ревматическими заболеваниями. Науч-практич ревма-тол 2005;4:34-8.Каратеев А.Е., Насонова В.А. Развитие и рецидивирование язв желудка и двенадцатиперстной кишки у больных, принимающих нестероидные противовоспалительные препараты: влияние стандартных факторов риска. Тер арх 2008;5:62-6.Saccar C. The pharmacology of esomeprazole and its role in gastric acid related diseases. Expert Opin Drug Metab Toxicol 2009;5(9):1113-24.McKeage K., Blick S., Croxtall J. et al. Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 2008;68(11):1571-607.Scheiman J., Yeomans N., Talley N. et al. Prevention of ulcer by esomeprazole in at-risk patients using non-selective NSAIDs or COX-2 inhibitor. Am J Gastroenterol 2006;101:701-10.Chan F., Wong V., Suen B. et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomized trial. Lancet 2007;369:1621-6.Hawkey C., Talley N., Yemans N. et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005;100:1028-36.Simon D., Botting R., Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004;56:387-437.Grosser T., Fries S., Fitzgerald G. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges an opportunities. J Clin Invest 2006;16:41.Hochman J., Shah N. What Price Pain Relief? Circulation 2006;113:2868-70.Hermann M. Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs. Curr Rheum Rep 2009;11(1):31-5.Cannon C., Curtis S., Fitzgerald G., et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Longterm (MEDAL) programme: a randomized comparison. Lancet 2006;18,368(9549):1771—81.Wang P., Avorn J., Brookhart M. et al. Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives. Hypertension 2005;46(2):273-9.Алексеева Л.И., Верткин А.Л., Иванов В.С. и др. Остеоартроз в практике врача-терапевта. РМЖ 2008;16(7):476—81.Lanas A., Tornero J., Zamorano J. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis 2010;69(8):1453-8.Ziegler S., Huscher D., Karberg K. et al. Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997—2007: results from the National Database of the German Collaborative Arthritis Centers. ARD 2010;69:1803-8.Имаметдинова Г.Р., Чичасова Н.В. Вольтарен в практике ревматолога. РМЖ 2007;15(26):1987—91.Каратеев А.Е., Насонов Е.Л. НПВП-ассоциированная патология ЖКТ: реальное состояние дел в России. РМЖ 2006;15:1073-8.Brun J., Jones R. Nonsteroidal antiinflammatory drug-associated dyspepsia: the scale of the problem. Am J Med 2001;110:12-3.Hollenz M., Stolte M., Leodolter A., Labenz J. NSAID-associated dyspepsia and ulcers: a prospective cohort study in primary care. Dig Dis 2006;24(1—2):189—94.Каратеев А.Е., Насонов Е.Л., Корешков Г.Г. НПВП-индуцированная диспепсия: распространенность и возможность медикаментозной коррекции. Науч-практич ревматол 2003;5:76-8.McGettigan P., Henry D. Cardiovascular risk and inhibition of cyclooxygenase. JAMA 2006;296:1633-44.Fosbil E., Folke F., Jacobsen S. et al. Cause-Specific Cardiovascular Risk Associated with Nonsteroidal Antiinflammatory Drugs among Healthy Individuals. Circ Cardiovasc Qual Outcomes 2010;3:395-405.Runkel R., Chaplin M., Boost G. et al. Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects. J Pharm Sci 1972;61(5):703-8.Aeidler H. Clinical results of a multicentral double-blind examination of naproxen compared to indomethacin in chronic rheumatoid arthritis, ankylosing spondylitis, and osteoarthrosis. Arzneimittelforschung 1975;25(2A):315-8.Bowers D., Dyer H., Fosdick W. et al. Naproxen in rheumatoid arthritis. A controlled trial. Ann Int Med 1975;83(4):470-5.Clarke A. A Double-blind comparison of naproxen against indometacin in osteoarthrosis. Arzneimittelforschung 1975;25(2A):302-4.Castles J., Moore T., Vaughan J. et al. Multicenter comparison of naproxen and indomethacin in rheumatoid arthritis. Arch Int Med 1978;138(3):362-6.Blechman W., Willkens R., Boncaldo G. et al. Naproxen in osteoarthrosis. Double-blind crossover trial. Ann Rheum Dis 1978;37(1):80-4.Melton J. 3rd, Lussier A., Ward J. et al. Naproxen vs aspirin in osteoarthritis of the hip and knee. J Rheum 1978;5(3):338—46.Martinez-Lavin M., Holman K., Smyth C., Vaughan J. A comparison of naproxen, indomethacin and aspirin in osteoarthritis. J Rheum 1980;7(5):711—6.Bjьrkenheim J., Helland J., Peltonen J. A double-blind crossover evaluation of naproxen and piroxicam in osteoarthritis of hip or knee. J Int Med Res 1985;13(5):263-9.Dunn T., Clark V., Jones G. Preoperative oral naproxen for pain relief after day-case laparoscopic sterilization. Br J Anaesth 1995;75(1):12-4.Comfort V., Code W., Rooney M., Yip R. Naproxen premedication reduces postoperative tubal ligation pain. Can J Anaesth 1992;39(4):349-52.Code W., Yip R., Rooney M. et al. Preoperative naproxen sodium reduces postoperative pain following arthroscopic knee surgery. Can J Anaesth 1994;41(2):98—101.Simmons R., Owen S., Abbott C. et al. Naproxen sodium and paracetamol/dextropropoxyphene in sports injuries — a multicentre comparative study. Br J Sports Med 1982;16(2):91-5.Singh G., Fort J., Goldstein J. et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med 2006;119:255-66.Bombardier C., Laine L., Reicin A. et al. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. N Engl J Med 2000;23,343(21):1520-8.Farkouh M., Kirshner H., Harrington R. et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet 2004;364:675-84.Capone M., Tacconelli S., Sciulli M. et al. Human pharmacology of naproxen sodium. J Pharmacol Exp Ther 2007;322(2):453-60.Van Hecken A., Schwartz J., Depre M. et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40(10):1109-20.Hinz B., Cheremina O., Besz D. et al. Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. Int J Clin Pharmacol Ther 2008;46(4):180-6.Schiff M., Hochberg M., Oldenhof J., Brune K. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Curr Med Res Opin 2009;25(10):2471-7.Trelle S., Reichenbach S., Wandel S. et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ 2011;342:7086 doi:10.1136.Ray W., Varas-Lorenzo C., Chung C. et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009;2(3):155-63.Gislason G., Rasmussen J., Abildstrom S. et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Int Med 2009;169(2):141-9.Roumie C., Choma N., Kaltenbach L. et al. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepid Drug Saf 2009;18(11):1053-63.Antman E., Bennett J., Daugherty A. et al. Use of Nonsteroidal Antiinflammatory Drugs. An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation 2007;115:1634-42.Burmester G., Lanas A., Biasucci L. et al. The appropriate use of non-steroidal antiinflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis 2011;70(5):818-22.Henry D., Lim L., Garcia Rodriguez L. et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312;1563—6.Castellsague J., Riera-Guardia N., Calingaert B. et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012;35(12):1127-46.Singh G., Mannalithara A., Sehgal A. et al. The Risk of Complicated Gastroduodenal Ulcers with Naproxen Is Dose-Dependent. Arthr Rheum 2010;62(10):926.Smalley W., Stein C., Arbogast P. et al. Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. Arthr Rheum 2002;46:2195-200.Sturkenboom M., Burke T., Dieleman J. et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003;42(Suppl 3):23-31.Van Soest E., Valkhoff V., Mazzaglia G. et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut. 2011 Jun 2. Epub ahead of print.Roberts D., Miner P. Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease. Drug Health Patient Saf 2011;3:1-8.Wang-Smith L., Fort J., Zhang Y., Sostek M. Pharmacokinetics and Relative Bioavailability of a Fixed-Dose Combination of Enteric-Coated Naproxen and NonEnteric-Coated Esomeprazole Magnesium. J Clin Pharmacol. 2011 May 31. Epub ahead of print.Miner P. Jr., Plachetka J., Orlemans E. et al. Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers. Aliment Pharmacol Ther 2010;32(3):414-24.Gladding P., Webster M., Farrell H. et al. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 2008;101(7):1060-3.Sibbing D., Morath T., Stegherr J. et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009;101(4):714-9.Scheiman J., Devereaux P., Herlitz J. et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsali cylic acid: a randomized, controlled trial (OBERON). Heart 2011;97(10):797-802.Angiolillo D., Hwang C., Datto C., Sostek M. Phase 1, randomized, doubleblind, placebo-controlled trial evaluating the antiplatelet effects of naproxen and esomeprazole magnesium (VIMOVOЄ) and concomitant low-dose aspirin. New Orleans, LA, USA: ACC, 2011.Goldstein J., Hochberg M., Fort J. et al. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs enteric-coated naproxen alone. Aliment Pharmacol Ther 2010;32(3):401-13.Chan F., Lanas A., Scheiman J. et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomized trial. Lancet 2010;376:173-9.Hochberg M., Fort J., Svensson O. et al. Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med Res Opin 2011;27(6):1243-53.Sostek M., Fort J., Estborn L. et al. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers. Curr Med Res Opin 2011;27(4):847—54.Ткаченко Е.И., Успенский Ю.П., Каратеев А.Е. и др. Гастроэзофагеальная рефлюксная болезнь: патогенетические основы дифференцированной тактики лечения. Экспер клин гастроэнтерол 2009;2:104-14.</div>

The authors declare that there are no conflicts of interest present.